INTRODUCTION AND OBJECTIVES: Peyronie's disease (PD)
is a connective tissue disorder of the tunica albuginea (TA) that results in penile deformity and has a high association with erectile dysfunction (ED). The mechanism of cavernosal dysfunction and subsequent ED is not well understood. Using human corpora cavernosa tissue, we explored the pathophysiology of ED in PD patients to determine if erectile tissue fibrosis occurs in a similar fashion as in the TA.
METHODS: Human corpora cavernosa tissues were removed during inflatable penile prosthesis implantation. Four patient groups were categorized as: (1) no PD and no ED (N[3), (2) PD and no ED (N[7), (3) PD and mild ED (N[7) and (4) PD and severe ED (N[7) . Diagnosis of PD was based on patient history and clinical examination. ED was categorized by penile Doppler-ultrasound findings as peak systolic velocity (PSV) 25mmHg/s (severe), between 25-35mmHg/s (mild) or PSV !35mmHg/s (no ED). Immunohistochemistry (IHC) for a-smooth muscle actin (a-SMA), Masson's trichrome and immunofluorescence (IF) for neuronal nitric oxide synthetase (nNOS) and CD34 (endothelial marker) were performed. Gene expressions of transforming growth factor (TGF)-b1, nNOS, endothelial NOS, inducible NOS, and Rho-GDI were measured by quantitative polymerase chain reaction (qPCR). RNA extracted from tissue samples was assayed by Nanostring nCounter ultra-high-throughput gene expression system for 255 inflammatory gene sets, including the common genes associated with TA fibrosis in PD.
RESULTS: There were no significant differences in baseline clinical or demographic characteristics. Using IHC and IF we did not observe a significant difference in markers for smooth muscle, fibrosis, or endothelial content, suggesting an absence of generalised wpenile corporal fibrosis. There was no significant difference in our gene expression by qPCR analysis (p[0.8). Nanostring bioinformatical analysis did not show a significant difference in any of the 255 inflammatory genes between the 4 groups.
CONCLUSIONS: This is the first study that examines ED using human erectile tissue from PD patients. Gene expression analysis of corpora cavernosa did not demonstrate the fibrosis or inflammation typically observed in the TA of PD. Our findings suggest that PD-related ED should not be attributed to inflammation or fibrosis in the corpora cavernosa and as such, favors a mechanical etiology of ED.
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MP65-20 THE EFFICACY OF BOTULINUM TOXIN TYPE A IN TREATING PEYRONIE'S DISEASE
Ali Antar*, Boriss Losso, James Anaissie, Jorge Rivera, Mohit Khera, Houston, TX INTRODUCTION AND OBJECTIVES: Botulinum toxin type A (BTA) has revolutionized the treatment of overactive bladder and other neurogenic lower urinary tract disorders. Acting primarily by reducing scar formation, BTA also shows promise as a treatment for other urologic scar-mediated diseases such as urethral stricture. Peyronie's disease causes curvature due to fibrosis and scar formation, thought to be due to the microtrauma associated with sex. Oral treatments are ineffective and with only one approved intralesional therapy (collagenase clostridium histolyticum)4, there is continued hope for novel treatments. The intent of this study is to determine the clinical efficacy of intralesional botulinum toxin type A injections to treat Peyronie's disease.
METHODS: This study is a randomized, placebo-controlled trial examining the use of intralesional BTA injections for the treatment of Peyronie's disease. The study included patients in the stable phase of Peyronie's and excluded patients with active Peyronie's, with multiple plaques, and calcified plaques. 12 patients were split into two treatment arms: 6 patients in arm 1 received 100 units of intralesional botulinum toxin type A injections and 6 patients in arm 2 received placebo. Both groups received injections every 2 weeks over 16 weeks for a total of 8 injections. Primary endpoints were International Index of Erectile Function (IIEF) scores and percent change in degree of curvature.
RESULTS: IIEF scores were not significantly improved in week 16 compared to week 1. Percent change in curvature was not significant. Full results are shown in the table below.
CONCLUSIONS: This study was not able to demonstrate clinically significant improvement in IIEF scores or percent change in degree of curvature. The study was significantly limited by small sample size and limited recruitment of patients with similarly matched degrees of curvature. The treatment modality shows promise and would warrant further investigation if future studies can focus on treating specified subsets of patients with a particular range of degrees of curvature. Copyright © 2019 American Urological Association Education and Research, Inc. Unauthorized reproduction of this article is prohibited.
